Roche Bets on Recursion AI to Develop Novel Neuroscience Drugs, Exploring New Pathways for AI-Driven Drug R&D

According to Bloomberg, Roche announced a collaboration with AI drug discovery company Recursion, betting on artificial intelligence technology to develop new drugs in the neuroscience field. This is one of the first attempts in the industry to adopt new AI methods to advance drug development. The background is that the neuroscience field has long faced the dilemma of unclear etiology—researchers still do not fully understand the pathogenesis of diseases such as Alzheimer's and Parkinson's, leading pharmaceutical companies to repeatedly target the same set of biological targets, with most attempts ending in failure. New-generation AI companies believe that leveraging AI technology holds promise to break through this bottleneck and significantly reduce drug trial failure rates.